Introduction
Since it was established that defects in collagen metabolism were associated with inherited connective tissue disease (McKusick, 1972) , considerable effort has been put into discovering the molecular basis of these genetic disorders. Up to 5 years ago a link between structural mutations in collagen genes and inherited connective tissue disease was considered likely, but there was little direct evidence to demonstrate the association (Sykes et al., 1977; Prockop et al., 1979) . But remarkable progress has since been made in analysing the molecular basis of inherited collagen disease at the gene level (Shapiro & Rowe, 1983 ; Prockop & Kivirikko, 1984; Byers & Bonadio, 1984) . This article reviews the recent progress in seeking out the molecular defects in collagen genes associated with inherited disease and discusses the impact this knowledge has on our understanding of the control of collagen biosynthesis and the pathology of the disorders. In addition, I consider present and future prospects for detecting other mutations with the ultimate aim of identifying patients at risk. The collagen family
The collagens are major structural components of the extracellular matrix. In vertebrates they consist of a family of at least 10 or more genetically distinct protein types, for which a minimum of 18 genes must exist to code for their constituent a chains (Table 1; see Bornstein & Sage, 1980; Miller & Gay, 1982; Burgeson, 1982 , for reviews). Collagenous molecules contain triple helical regions characterized by the presence of a basic repeating triplet unit of amino acids consisting of Gly-Xaa-Yaa. Although a variety of amino acids occupy the Xaa and Yaa positions, proline and hydroxyproline often occupy the Xaa and Yaa positions respectively. This triplet unit is essential Abbreviations used: OI, osteogenesis imperfecta; EDS, Ehlers Danlos syndrome; pro-a,ls shortened proal(I) chain; type Iss, type I collagen with two shortened al(I) chains; CB, CNBr peptide; kb, kilobases; bp, base pairs; RFLP, restriction fragment length polymorphism.
for the formation of a semi-rigid triple-helical molecule composed of three chains. It is the variation in length, primary structure and the presence, extent and location of both noncollagenous domains and interchain disulphide-bonding which form the basis for categorizing the different collagen types.
The types, quantity, and occasionally the molecular composition (type V) of collagen expressed varies in different tissues (Table 1; Bornstein & Sage, 1980; Hollister et al.., 1983; Alitalo et al., 1983; Shimokamaki et al., 1980; von der Mark et al., 1982; Odermatt et al., 1983; Sage et al., 1981 Sage et al., , 1983 Haralson et al., 1980 Haralson et al., , 1984 Niyibizi et al., 1984) . Types I-III have been classed as interstitial collagens, having a fibrillar structure. Of the nonfibrillar collagens, type IV, a major component of basement membranes, is best understood. The remaining types are not well characterized and are usually present in small amounts. While structurefunction relationships of the different collagens remain to be defined, it is believed that the coordinate expression of these collagen genes is important in vertebrate development and differentiation (Adamson, 1982) . There is also evidence indicating that the expression of type I collagen during development is essential for life. Its absence cannot be compensated for by other collagen types. This is illustrated by the finding that the integration of a retrovirus into the 5' end of the al(I) gene results in developmental arrest in early mouse embryos which is lethal (Schnieke et al., 1983; Harbers et al., 1984; Lohler et al., 1984) .
To date the gene structures for only a few collagen a chains have been determined. (Table 2 ). The complete structure of the chicken a2(I) gene was the first to be established (see Cheah & Grant, 1982; Boedtker et al., 1983 , for reviews). From these studies a remarkable picture emerges for collagen gene structure. Although a minimum of 5kb is required to code for a pro-a2(I) chain (1500 amino acids) it was found that the actual size of the chicken gene was approx. 40kb divided into 51 Table 1 . The vertebrate collagen gene family: types, molecular composition and tissue distribution Types I-V collagen has been the best characterized but a number of other collagen types have been recently discovered [Furthmayr et al. (1983) , Odermatt et al. (1983) (type VI); Bentz et al. (1983) (type VII); (type VIII); Mayne et al. (1984) , Ninomiya & Olsen (1984) , van der Rest et al. (1985) (type IX); Gibson et al. (1982 Gibson et al. ( , 1983 , Schmid & Conrad (1982) , Kielty et al. (1985) (type X)] and some await type assignments [Burgeson & Hollister (1979) , Reese & Mayne (1981) , Burgeson et al. (1982) (Chu et al., 1984) . Another distinctive feature of these genes is the presence of 45, 54, 99 and 108 bp exons which encode exact multiples of Gly-Xaa-Yaa triplets, in the regions which code for the triple-helical domains. Exons of 54 and 108bp are most common in this domain and variations thereof could have originated by removing or adding the coding potential for a Gly-Xaa-Yaa triplet. It has therefore been suggested that collagen genes arose by duplication and recombination of an ancestral 54bp primordial gene  reviewed by Solomon & Cheah, 1981; Boedtker et al., 1983) . This 54bp exon size is co mmon to all the fibrillar collagen genes isolated thus far Sandell et al., 1983 Sandell et al., , 1984 Chu et al., 1984; Cheah et al., 1985) . But it is of note that 54bp exons are not seen in the helical coding region of the genes for nonfibrillar collagens in two invertebrates, Drosophila and nematode (Monson et al., 1982; Kramer et al., 1982 an illustration from which general principles may be applied for the other collagens (Fig. 1) . Detailed descriptions of this process may be found in reviews by Grant & Jackson (1976) , Fessler & Fessler (1978 ), Prockop et al. (1979 . Type I collagen is synthesized as a precursor molecule, procollagen, consisting of two pro-al(I) chains and a pro-a2(I) chain which associate to form a triple helix with globular domains at the Nand C-termini, the N-and C-propeptides. As illustrated in Fig. 1 , there are many steps in this complex process at which errors in biosynthesis may occur and lead to the production of a faulty collagen molecule, hence contributing to the pathology of disease.
Inherited collagen disease
Genetic disorders of collagen metabolism usually affect tissues in which the proper development and integrity of connective tissue is of paramount importance (for reviews see Hollister et al., 1983; Pinnell & Murad, 1983; Krane, 1984) . Hence the majority of these disorders affect bone (osteogenesis imperfecta; 01), skin and joints (Ehlers Danlos syndrome; EDS), arteries (Marfan syndrome) and cartilage development (chondrodystrophies). They form an extremely heterogeneous class within the wider category of heritable disorders with connective tissue involvement which include cutis laxa (loose, inelastic skin), Menkes syndrome (abnormal copper metabolism), epidermolysis bullosa (abnormal and repeated blister formation) and alkaptonuria (degenerative joint disease). However, not all these inherited diseases are associated with structural defects in collagen genes. The first true molecular defect in collagen metabolism to be identified was due to lysyl hydroxylase deficiency in EDS VI (Pinnell et al., 1972) Hollister et al., 1983 , for reviews). Because of the relative ease of obtaining skin biopsies this tissue has been most extensively studied, whether the primary defect is in skin, bone or arteries . Abnormalities in general collagen fibre structure in skin are seen for a wide range of inherited disease e.g. EDS, 01, pseudoxanthoma elasticum, cutis laxa, Marfan syndrome, etc. But these studies also show that there are no unique disease-specific structural alterations in collagen fibril structure. In addition, there is difficulty in correlating morphological changes with biochemical changes. Intracellularly, engorged endoplasmic reticulum has also been observed in skin fibroblasts from OI and EDS patients (Byers et al., 1979; Holbrook & Byers, 1981; Hollister et al., 1983; Steinmann et al., 1984) , and there is evidence for the accumulation of type I procollagen in OI cells (Barsh & Byers, 1981) . These morphological changes may be symptomatic of structural abnormalities within the molecule which result in reduced secretion.
Biochemical analyses probe deeper for the defect. Again, because of the heterogeneity of inherited collagen disease, it has been difficult to assign specific biochemical characteristics to each type or sub-class. However the primary collagen defect in a small number of patients has been successfully identified. Comparisons of amino acid compositions, levels of hydroxyproline and hydroxylysine and the extent of glycosylation in collagen isolated from patient and control tissue may indicate the primary cause of the defect Hollister, 1981; Byers et al., 198 la; Hollister et al., 1983) . The relative amounts of the different collagens in the affected tissue may also indicate the nature of the abnormality. For example, altered type III:type I collagen ratios have been found in the skin from a number of OI patients (Sykes et al., 1977; Barsh et al., 1982) and have been shown to be due to reduced type I production. The absence or reduction of type III collagen synthesis in skin fibroblasts from patients with EDS IV has been shown (Pope et al., 1975; Aumailley et al., 1980; Hollister et al., 1983) , although there is an instance where normal amounts have been found (Sulh et al., 1984) . Inappropriate expression of collagen type may also play a role in the pathogenesis of disease. Two examples of perinatal lethal OI have been reported where type III collagen was found in bone in which it is not normally present. Also, the level of type V collagen in 01 bone was elevated (Pope et al., 1980) .
Comparison of the molecular sizes of the collagen and pro-a chains by gel electrophoresis or column chromatography may reveal structural alterations in these chains. But the extent of posttranslational modification affects the relative mobilities of collagenous molecules in polyacrylamide gels (Cheah et al., 1979) . Thus, comparative studies of the procollagen chains synthesized in the presence or absence of inhibitors of hydroxylation often enable an apparent Mr change due to a structural defect in the molecule to be distinguished from one arising because of faulty processing enzymes (Barsh & Byers, 1981; Byers et al., 1983a; Bonadio et al., 1985) .
The collagen molecule itself contains several landmarks which have proven useful for the determination of approximate locations of structural The pathway of synthesis of procollagen type I from transcription of the acl(I) and a2(I) genes to fibril formation is shown diagrammatically. The genes for pro-a l(I) and pro-oa2(I) chains are transcribed and the 50 introns excised to yield the mature transcript. These procollagen mRNAs are translated on membrane-bound polysomes (Cheah & Grant, 1982 , for review) and pre-pro chains containing signal peptides at their N-termini are synthesized. The signal peptides are cleaved off within the rough endoplasmic reticulum, glycosylation, hydroxylation, disulphide bonding and helix formation occurs and the mature procollagen molecule is secreted to the extracellular matrix. Outside the cell the propeptides are cleaved by specific N-and C-proteinases and the collagen monomers are assembled to form collagen fibres by aggregation and cross-linking. The drawing of the human al1(I) gene is reproduced from Chu et al. (1984) and is reprinted with the permission of the authors and of the publishers (Macmillan Journals Ltd.). The structure of the chicken a2(I) gene is reproduced from Vogeli et al. (1980) (Fessler & Fessler, 1978) . Mammalian collagenases cleave type I collagen once, specifically within the helix, to give two fragments, one onequarter (C-terminal, B fragment) and the other three-quarters (N-terminal, A fragment) the length of the original molecule (Werb, 1982) . In the extracellular matrix, N-and C-proteinases cleave off the N-and C-propeptides at specific sites (Heathcote & Grant, 1980) . Direct analysis of collagen gene structure has been the most recent experimental approach in the search for the cause of inherited collagen disease and in the study of their genetics. For this the availability of DNA probes for human collagen genes is essential and to date ones for types I-III have been isolated (Table 2 ). These probes may be used to detect insertions and deletions in the genes. Collagen gene probes may also be used to screen for polymorphic markers with which one may detect the defective locus or predict the occurrence of an inherited disease by linkage analysis. Apart from structural comparisons, biosynthetic studies of collagen mRNAs and the rates of synthesis and degradation of pro-a chains in normal and patient tissue provide important indications for the site of the primary defect.
In the vast majority of patients studied no abnormality in collagen at the primary level has been detected. But using a combination of all these experimental approaches described above the molecular basis of inherited collagen disease in a small number of patients has been determined. Structural mutations in type-I collagen genes The structural alterations found in type I procollagen in patients with 01, EDS and Marfan syndrome are illustrated and described in Fig. 2 and at half the rate of normal cells and there was increased intracellular accumulation of these molecules. Analyses of the pro-al (J) chains synthesized by these cells in the presence or absence of a'adipyridyl, an inhibitor of hydroxylation, indicated that half the pro-al(I) chains were altered in length, but not the pro-cz2(I) chains (Barsh & Byers, 1981) . It was proposed that the abnormal type I procollagen molecules contained either one or two shortened pro-al(I) chains (pro-als). The population of type I procollagen molecules therefore consisted of normal type I, ones with one short proal(I) chain (type Is) and ones with both pro-c I(I) chains shortened (type ISS) in the ratio of 1:2: 1 . Pro-als chains were able to associate with pro-a2(I) chains to form a triple helix although such molecules (type Is and type ISS) were less thermally stable and were not cleaved by procollagen N-proteinase. Because the melting temperature of the abnormal molecules was reduced below 37°C it was also unlikely that they could remain helical at body temperature. Molecules with one shortened al (I) chain were also secreted more slowly (hence the observation of intracellular accumulation) and were rapidly degraded in the extracellular matrix. Those containing two shortened chains were either not secreted or degraded even more rapidly. Cell-free translation of mRNA from these cells yielded shortened and normal-sized pro-a l(I) chains, indicating that the defect lay in the gene .
Digestion of the abnormal trimers with mammalian collagenase indicated that the shortening of the pro-al(I) chain lay N-terminal to the cleavage site. Because the entire gene for human axl(I) collagen has been isolated it was possible to locate the exact position of the missing portion of the chain. Using a combination of cDNA and genomic probes an internal deletion of approx. 500bp was found in one allele . DNA sequencing of the isolated defective allele reveals that the deletion effectively removed three exons (nos. 27-29) coding for 84 amino acids in the triple helix (amino acids 328-411) (Barsh et al., 1985; Chu et al., 1985a) . The loss of 84 amino acids but the retention of the reading frame therefore resulted in the synthesis of shortened pro-al(I) chains which could form a triple helix, albeit of reduced stability. Despite heterozygosity, the severity of the disease in this patient leading to perinatal death was probably because the molecular composition of type I collagen ensured that three-quarters of the molecules synthesized were abnormal and therefore ineffective in providing adequate tissue integrity. There was also some evidence for an elevation of type III collagen synthesis and gene expression Chu et al., 1985a) , perhaps in a compensatory attempt to overcome the type I deficiency. It is significant, however, that as for the developmentally lethal homozygous mutations in the mouse al(I) gene (Schnieke et al., 1983 , Lohler et al., 1984 , the defect could not be overcome by increased synthesis of another collagen type.
Lengthening of al(I) chains may also result in lethal disease. In two patients with lethal 01 all pro-a chains synthesized were lengthened (Uitto et al., 1983) and the pro-a chains were post-translationally overmodified, possibly because of a reduced rate of helix formation. The location of the lengthening in the pro-al (I) chain was tentatively assigned to CNBr peptide CB6 which is located beyond amino acid residue 820 in the helix. The exact effect of lengthening pro-al(I) chains on helix formation and on the functional ability of the resulting type I collagen molecules remains to be defined. But it is likely that nonfunctional helices may be formed also with deleterious effect.
There is evidence that a mutation resulting in complete non-function in one al(I) allele may cause disease but is less severe than one producing malfunctioning type I collagen molecules as just described. Barsh et al. (1982) have studied three patients with less severe, non-lethal type of 01 (type I) in which reduced levels of type I collagen was found in bone and skin. Cultured skin fibroblasts from these patients synthesized onehalf the normal level of type I collagen which was reflected in the amount of a 1(I) chains, since proal(I) and pro-a2(I) chains were in a 1 :1 ratio instead of the normal 2:1. mRNA levels for proal(I) were also reported to be reduced (D. Rowe, personal communication; Byers & Bonadio, 1984) . A non-functioning allele for pro-al(I) was suggested to be the cause for this defect. One may speculate that the lesser severity of this type of 01 type I is because no abnormal al (I) chains capable of being incorporated into a triple helix were synthesized. Hence all type I collagen molecules synthesized were normal, albeit at reduced level within the critical limit for life. This is a less severe situation than one in which three-quarters of the type I collagen molecules are abnormal, probably not helical at body temperature and rapidly degraded. The absence of triple-helical molecules composed of a2(I) chains confirms that they are unable to form triple helices and therefore unlikely to act as functional substitutes for al(I).
The stability and formation of the collagen triple helix is dependent on the conservation of the GlyXaa-Yaa triplet. Destabilization of the type I collagen helix may result by substituting another amino acid for a glycine residue. Steinmann et al. (1984b and B. Steinmann, personal communication) have shown in skin fibroblasts from an OI type II patient that the substitution of a cysteine residue for glycine (residue 988) in CNBr peptide CB6 (towards the C-terminus) within one or both al(I) chains of the triple helix results in reduced thermal stability of type I collagen, increased posttranslational modification, increased intracellular degradation of collagen and decreased collagen production. In addition, collagen fibrils were found to be thinner than normal and abnormal intramolecular and interchain disulphide bonding was observed.
The molecular and functional effect of such a mutation remains to be proven. But this substitution probably delayed helix formation and would account for the increased post-translational modification, since hydroxylation and glycosylation do not occur once a helix is formed (Kivirikko & Myllyla, 1982 although the location and effect on collagen biosynthesis has not yet been identified.
Structural alterations in a2(I)
The other well-characterized example of a structural mutation in type I collagen is in a patient with type III (moderately severe) 01, first noted by Nicholls et al. (1979) because of the apparent absence of pro-a2(I) chains in the collagen synthesized. All the collagen synthesized by the skin fibroblasts of the patient consisted of a trimer of pro-al (I) chains. Subsequent study revealed that pro-a2(I) mRNA was present and pro-a2(I) chains were in fact synthesized both in cell-free translation and within the cells. But these pro-a2(I) chains could not associate with pro-al(I) chains (Deak et al., 1981 (Deak et al., , 1983 . Because triple-helix formation begins at the C-terminus (Bachinger et al., 1981; Bruckner et al., 1981) and is dependent on the correct alignment of the C-propeptides it was likely that the primary defect lay within that region. Analyses of the mRNA and the isolated defective allele confirm this premise. Dickson et al. (1984) tested for mismatched regions between the mRNA and the coding regions of the gene by S1 nuclease digestion of RNA-DNA hybrids. These studies uncovered a region of mismatch within exon 1 of the a2(I) gene about 35 amino acids from the termination codon. This mismatch was found to be a 4bp deletion in the gene which caused a frameshift mutation and created a new termination codon 3' to the original site (Pihlajaniemie et al., 1984) . Consequently the amino acid sequence of the last 33 amino acids of the a2(I) chain was altered, changing the proportions of charged residues and creating a new cysteine residue. The phenotypic consequence of this mutation is that pro-a2(I) chains cannot form a triple helix with pro-al (I) chains, confirming the critical role of the C-propeptide in helix formation. A secondary observation, as yet unexplained, was that proa2(I) chain synthesis was decreased. This example also implies that, unlike a 1(I), the presence of a2(I)
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There is preliminary evidence that a deletion of approx. 100 amino acids from the central portion of the triple helical domain of a2(I) chains is the cause of another example of lethal 01 (Byers et al., 1983b; Byers & Bonadio, 1984) . Both normal and shortened a2(I) chains were synthesized; however, helical molecules containing the mutant chains were unstable at 37°C and were degraded intracellularly. Other deletions in the a2(I) gene or shortening of pro-a2(I) chains have been reported. Interestingly, a number of these could correspond to a deletion of a 54bp exon (18 amino acids or 6 Gly-Xaa-Yaa triplets). Fibroblasts from a type II 01 patient synthesized only pro-a2(I) chains which were shortened by approx. 20 amino acids but could still form a helix . Digestion of the collagen with vertebrate collagenase and CNBr place the shortening in the peptide 2CB3/5A, which lies in the middle of the helix (amino acids 361-775). A preliminary report of Rlooping analysis of DNA-mRNA hybrids showed that exon 25, coding for 18 amino acids (i.e. a 54bp exon), had been deleted (Sippola et al., 1984b) . Because neither of the proband's parents synthesized shortened a2(I) chains it was considered unlikely that both alleles could have mutated identically in the generation of a new mutation. But a2(I) mRNA levels and a2(I) chain synthesis were reduced in both father and patient. It was likely therefore that the shortened a2(I) chains originated from a mutated allele which was expressed while the other allele was not, or produced unstable transcripts. Similar-sized mutations are also probably involved in two other patients with a milder variant of OI intermediate between type I and III (Byers et al., 1983a; Sippola etal., 1984a) . Both show a shortening by approx. 20 amino acids in the a2(I) CNBr peptide CB4. There is also a preliminary report in one patient that this is correlated, by R-looping, with the deletion of exon 42, a 54bp exon (Sippola et al., 1984b) .
It is interesting that in one situation a deletion of 18 amino acids is associated with a lethal form of OI, and yet another similar-sized mutation is seen in the context of mild to moderate 01. In the former, it is possible that it is the combination of a null allele together with one containing a-deletion, so that all type I collagen molecules produced are abnormal, that results in lethality. In the latter, normal a2(I) chains were also synthesized and therefore a proportion of normal type I molecules (Byers et al., 1983a) were present. It is also possible that the loss of exons coding for different parts of the protein molecule result in varying severity and may be tolerated depending on whether they occur in an important functional domain.
One consequence of an altered primary structure may be non-cleavage of the propeptides because of a modification of the proteinase recognition sites or incorrect folding of the N-terminus. Two such examples have been reported. Steinmann et al. (1980) found that cultured skin fibroblasts from a patient with EDS type VII produced two classes of type I procollagen molecules. One was normal but the other was resistant to cleavage by procollagen N-proteinase. Hence partially processed pro-a2(I) chains [pN-a2(I) ], in which the N-terminal peptide remained, were present. In the report on a patient with clinical characteristics of both milder OI and EDS, the shortening of the pro-a2(I) chain by approx. 30 amino acids in a2(I)-CB4 apparently also results in the persistence of partially processed pN-a2(I) chains and a proportion of thermally unstable molecules on a background of normal ones (Sippola & Prockop, 1983; Sippola et al., 1984a) . Insertions have also been implicated in inherited collagen disease. Byers et al. (1981b) reported the first incidence of an insertion of 20 amino acids in the a2(I) chain in a Marfan patient. Skin fibroblasts from the patient synthesized normal and lengthened a2(I) chains. The source of the extra material was located N-terminal to the vertebrate collagenase site in a2(I) CNBr peptides CB3 or CB5. The consequence of this insertion seems to be a reduction in crosslinking between type I collagen molecules, although the fibrils themselves were not altered morphologically. The molecular and biochemical basis for disease^in this patient still remains obscure. An attempt has been made to isolate the defective a2(I) allele in this patient but so far only an insertion of 38 bp within an intron, has been found (Henke et al., 1985) . It is uncertain whether the additional material lay within the normal or altered allele, since it could not have caused a 20 amino acid deletion. The relationship of this 38 bp insertion to the disease therefore remains unclear and may reflect small polymorphisms in fragment length which may occur normally (discussed later). There has also been a preliminary report of an insertion in the a2(I) CB4 peptide in a patient with EDS type VII (Steinmann et al., 1985) . Both normal and abnormal a2(I) chains were observed, but again the role of this change in the aetiology of the disease is unknown.
Structural mutations in other collagen genes
The involvement of other collagen genes in the pathology of inherited connective tissue disease has not been well studied. The observed absence or reduction in level of type III collagen in EDS IV patients (Pope et al., 1975; Aumailley et al., 1980; Byers et al., 1981a ) point towards a defect in the al (III) collagen gene. Pyeritz et al. (1984) report on an EDS IV patient with markedly reduced levels of type III collagen content in skin. Skin from the patient synthesized normal amounts of pro-a 1(III) mRNA but secreted pro-al(III) chains of normal and abnormal electrophoretic mobility which were unusually sensitive to proteolytic degradation. The defect in the pro-al(III) chain is probably an insertion of about 20 amino acids in CNBr peptide CB5 in the region of residues 555-775 (Pyeritz et al., 1984; Stolle et al., 1985) .
Molecular mechanisms and disease phenotype
From the above studies it appears that the severity of an inherited collagen disease may depend on a number of factors. Small or large changes in type I procollagen structure may result in the same or different clinical phenotype depending on the part of the molecule affected and the proportion of abnormal trimers formed. Lethal OI has now been seen in several contexts. Alterations in al(I) appear to be more severe in consequences probably because a defect in one allele will affect 75% of the procollagen I molecules. The consequence of changes in a2(I) vary in severity possibly because, in the heterozygous state, 50% normal type I collagen is synthesized if the a2(I) chain is capable of forming a helix with al(I). If only type I trimer is made instead, all molecules would contain normal al(I) chains, but this class of collagen obviously cannot fully replace type I collagen in function. It is uncertain exactly what level of reduction in procollagen I production is incompatible with life. Furthermore, the precise effect of a mixture of abnormal and normal collagen molecules on the function of the tissue (e.g. bone for 01) and in causing the disease is still unknown. It is clear however that alterations in type I collagen probably play a major role in causing some forms of 01, EDS and Marfan syndrome. Since type I collagen is the main collagen component of skin, bone and arteries, its involvement with disease possibly explains the overlapping characteristics seen in OI and EDS and suggests that alteration in type I collagen can affect the extracellular matrix as a whole. Considering the data available, it has been suggested however that the type of mutation and its position in the molecule may affect the resulting clinical phenotype (Byers & Bonadio, 1984; Bonadio et al., 1985) . According to this hypothesis alterations in the C-terminal 400 residues of the triple helix of type I collagen would result in type II 01, whereas N-terminal modification would produce type III OI. Nevertheless, it is difficult to make similar predictions for the different diseases without more extensive evidence.
It is unlikely that lesions in type I collagen will account for all the inherited collagen disease. Other contributory factors are probably involved. Changes in the other collagen types normally present in smaller amounts have not been well studied. But there is some evidence for an insertion in pro-al(III) chains in one form of EDS (IV) (Stolle et al., 1985) and inappropriate expression of type III collagen and elevated type V levels in 01 bone (Pope et al., 1980) . Within the extracellular matrix, collagen interacts with proteoglycans and glycoproteins (Lindahl & Hook, 1978) some of which are tissue specific. For example, some noncollagenous matrix proteins are specific to bone. These include osteonectin (Termine et al., 1981) , bone proteoglycan (Fisher et al., 1983a ) and bone sialoprotein (Fisher et al., 1983b) . Osteonectin binds to hydroxyapatite and collagen and promotes mineral deposition onto type I collagen (Termine et al., 1981) . It is interesting that in bovine osteogenesis imperfecta, in addition to the reduction in collagen content often seen in the human context, there was a marked depletion of osteonectin and proteoglycans. Sialoprotein content was also reduced but to a lesser extent (Termine et al., 1984) . Arneson et al. (1980) have described a family with features of EDS I or II in which abnormalities in fibronectin have found in affected members. Also, in a Marfan patient while collagen amounts were normal, the amino acid, desmosine and isodesmosine compositions of elastin were abnormal, and levels were reduced (Abraham et al., 1982) . Elastin is a major matrix component of arteries, the affected tissue in Marfan patients. Altered elastic fibrils have been observed in skin from patients with cutis laxa and EDS . It is likely that changes in other collagenous and noncollagenous matrix components pass undetected because the majority of studies are on cultured skin fibroblasts, whereas the major affected tissue may be bone or artery or cartilage. But, at present, the precise effect of changes in matrix composition on tissue function remains uncertain.
Technical limitations and possible solutions
The molecular basis of inherited disease for at least two patients was discovered because of the application of recombinant DNA technology to systems where the collagen biochemistry was well understood. The isolation of DNA probes for entire human collagen genes has been essential for detecting mutations affecting any part of the collagen molecule. It is only within this past year that the human al(I), a2(I) and al(II) collagen genes have been completely isolated (Table 2 ).
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However, there are limitations in the use of conventional methods for the detection of mutations in collagen at the protein and gene levels.
At the protein level, the limit of detection of an alteration in pro-a chain size is 15-20 amino acids. At the DNA level the lower limit for detecting insertions or deletions in collagen genes against a background of total genomic DNA without cloning the defective gene is approx. 100bp. These methods therefore cannot detect small deletions and insertions or point mutations, single base changes and amino acid substitutions. Of course it is possible to clone the collagen genes from each patient and seek out changes over the entire DNA sequence, but is impractical because of the size of these genes with so many exons. There is therefore a necessity to develop other methods for detecting and locating small changes in procollagen. Nuclease treatment of hybrids formed between cloned single-stranded DNA and total genomic DNA have been recently used to detect small changes in globin genes (Chebloune et al., 1984; Myers et al., 1985) and may have similar applications for collagen genes.
In most of the examples of structural changes in procollagen, including a single amino acid substitution, all or half the pro-a chains were overmodified and were less thermally stable. Byers and coworkers have suggested that this change in physical property in pro-a chains may be a symptom of small changes e.g. single amino acid substitutions (Byers & Bonadio, 1984; .
They postulate that amino acid substitutions which involve glycine in the repeating triplet will destabilize the helix and hence slow down the rate of helix formation from that point onwards.
Because post-translational modification of chains ceases once a helix is formed, a non-enzymic reason for increased hydroxylation and glycosylation could be delayed helix formation. The region at which increased post-translational modification begins may pinpoint the appropriate location of a small insertion, deletion or substitution. But this method has three limitations. It does not distinguish which a chain in the type I helix carries the defect. Also, modifications which occur towards the N-terminus [beyond al(I)CB8] are difficult to localize. Finally, defects which alter other properties of the type I molecule not associated with posttranslational modification cannot be detected. These findings are interesting, however, because once such a region is identified it may be possible to determine the exact molecular defect using the appropriate DNA probes, much in the same way that the frameshift mutation was identified in the type III 01 patient . In several cases of 01, mixed populations of normal and partially or wholly over-modified type I collagen were found in the absence of any other detectable difference in molecular size (Bateman et al., 1984; Sayed et al., 1984; Wenstrup et al., 1984; Bonadio et al., 1985) and may be symptomatic of changes which cause delayed helix formation. DNA polymorphisms, linkage studies and prenatal diagnosis Another important aim in studying the molecular basis of inherited collagen disease is the detection of patients at risk. In order to offer prenatal diagnosis it may not be always necessary to determine the biochemical basis for an inherited disease. Variations exist in the DNA base sequence within and around genes. These give rise to DNA fragments of varying lengths when cleaved by restriction endonucleases. The existence of restriction fragment length polymorphisms (RFLP) has been useful for the analysis of inherited disease. Some RFLPs may be linked with defective genes where these are known, e.g. those in the globin gene cluster associated with the thalassaemias (Orkin et al., 1982) . Others may act as linkage markers for an inherited disease without being directly involved in the causation of the disorder, e.g. Duchenne muscular dystrophy and Huntington's disease (Murray et al., 1982; Gusella et al., 1984) . The (Huerre et al., 1982; Solomon et al., 1984b) and the a2(I) gene is on chromosome 7 Solomon et al., 1983) . Three others are likewise dispersed: the ol(II), al(III) and al(IV) genes are on chromosomes 12, 2 and 13 respectively (Solomon et al., 1984a . The type I and II collagen genes are present in single copies (Dalgleish et al., 1982; Tsipouras et al., 1983; R. Dalgleish, unpublished work) . In a search for RLFPs in collagen genes, an EcoRI and a MspI site polymorphism has been found in the a2(I) gene (Tsipouras et al., 1983 . The EcoRI polymorphism, which lies in the 5' end of the gene, occurs at a high allelic frequency and has been found to segregate with mild autosomal dominant types of 01 (types I and IV) in two families. This suggests that the clinical phenotype in this family may be linked to a defect in the a2(I) gene. However in three other families with autosomal dominant OI there was no linkage with the disease and illustrates the heterogeneity of these disorders. By similar analyses of HindIlI and PvuII site polymorphisms in the type II collagen gene, the involvement of this locus in three families with autosomal dominant 01 type I has been excluded (Sykes et al., 1985a) . Using the HindIII polymorphism, type II collagen has also been excluded as the defective locus in one family with EDS type II (Wordsworth et al., 1985) .
The polymorphic sites reported for the type II collagen gene and its 3' flanking region should also prove useful for the genetic analysis of the chondrodysplasias. The HindlIl site polymorphism (Driesel et al., 1982; Sykes, 1983) occurs with high frequency and has a neutral ethnic distribution. There is also a variation in an EcoRI fragment length which was first observed in several families with a history of perinatal lethal 01 ) and now appears to occur in West Indians and Asian Indians at higher frequencies than in Caucasians (Sykes & Ogilvie, 1984; Sykes et al., 1985b; F. M. Pope, unpublished work) . The EcoRI fragment length variation lies in the region immediately 3' to the type II collagen gene Cheah et al., 1985) . This is the first length polymorphism within a single fragment close to a collagen gene to be reported which also appears to have a frequency which is ethnic-group-associated. Two variants of this gene have been isolated (K. S. E. Cheah, unpublished work). From this and other studies the variation in length of the EcoRI fragment appears to range from deletions of 30bp to 300 bp, to an insertion of 100bp when compared with the commonest fragment size (Sykes et al., 1985b; F. M. Pope, unpublished work) .
Instead of RFLPs, diminished cl(I) mRNA levels have been used as a marker for dominantly inherited 01. Reduced levels of al(I) mRNA segregated with affected individuals within a three-generation family (D. Rowe, personal communication). This is unlikely to be a popular means for prenatal diagnosis because of the length of time and expense required to establish primary skin fibroblasts from many individuals. Measurements of mRNA levels are also subject to experimental artefacts associated with possible increased degradation and instability of the mRNA during extraction.
At present techniques for prenatal diagnosis of 01 and achondroplasia are by ultrasound, radiography and the analysis of the procollagen synthesis of amniotic fluid cells (Shapiro et al., 1982; Aylsworth et al., 1984) . These methods are disadvantaged by the lateness at which the disease may be detected (19-25 weeks of gestation). Also only type I and IV collagen synthesis may be monitored in the amnion (Crouch & Bornstein, 1978 . Of the inherited diseases those involving the type II collagen gene may be the most difficult to analyse for several reasons. Skin fibroblasts do not synthesize type II collagen and cartilage biopsies are both difficult to obtain and to maintain phenotypically and biochemically in long-term culture. Biosynthetic studies are therefore severely handicapped. The use of RFLP linkage studies may therefore be of particular importance for the diagnosis and detection of a type II collagen gene defect with subsequent gene cloning as a means of determining the molecular basis of the disease.
Prenatal diagnosis is not possible for parents of lethal 01 patients where the biochemical basis is that of a new mutation, as has been found in several cases Steinmann et al., 1984b; Bonadio et al., 1985) .
Future prospects
It is certain that linkage studies of polymorphic restriction enzyme sites will be used increasingly as a tool both to provide a pointer to the molecular defect and for prenatal diagnosis. For disorders involving types I and III collagen the future is promising for detecting gross structural alterations in the genes and the protein. Accompanying such discoveries will be a greater understanding of the functional importance of the different collagen types and their intramolecular domains. It will be harder to detect fine changes, e.g. point mutations or amino acid substitutions, but it is likely that new techniques for detecting these will be devised. For example, heterokaryons formed by cell fusion have been used in an attempt to detect mutations in type I collagen genes (Byers & Bonadio, 1984 
